Oncocyte Corporation - Common Shares, No Par Value (OCX)

CUSIP: 68235C107

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Shares, No Par Value
Shares outstanding
28,495,649
Total 13F shares
47,078
Share change
-12,275
Total reported value
$112,046
Price per share
$2.38
Number of holders
1
Value change
-$29,215
Number of sells
1

Quarterly Holders Quick Answers

What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
BROADWOOD CAPITAL INC
13F
Company
15%
4,929,066
$14,047,838 30 Sep 2024
13F
Patrick W. Smith
13D/G
10%
1,773,903
$4,221,889 $0 26 Dec 2024
AWM Investment Company, Inc.
13F
Company
3.4%
1,097,175
$3,126,949 30 Sep 2024
13F
PURA VIDA INVESTMENTS, LLC
3/4/5 13F
10%+ Owner · Company
1.5%
from 13F
16,591,052
mixed-class rows
$3,044,309 14 Apr 2023
VANGUARD GROUP INC
13F
Company
0.76%
245,388
$699,356 30 Sep 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.32%
103,980
$296,400 30 Sep 2024
13F
BlackRock, Inc.
13F
Company
0.25%
79,833
$227,525 30 Sep 2024
13F
MORGAN STANLEY
13F
Company
0.22%
72,289
$206,024 30 Sep 2024
13F
Defender Capital, LLC.
13F
Company
0.21%
59,353
$169,156 30 Sep 2024
13F
John Peter Gutfreund
3/4/5
Former Director
mixed-class rows
760,000
mixed-class rows
$153,654 30 Jun 2023
Ronald Asbury Andrews
3/4/5
Former CEO, Director
mixed-class rows
633,212
mixed-class rows
$125,332 01 Dec 2022
FNY Investment Advisers, LLC
13F
Company
0.13%
42,896
$122,000 30 Sep 2024
13F
Alfred D. Kingsley
3/4/5
Director
mixed-class rows
597,878
mixed-class rows
$109,143 23 Jun 2023
Gisela Paulsen
3/4/5
Former President and COO
class O/S missing
366,500
$78,761 16 Dec 2022
Li Yu
3/4/5
VP Cntrllr/Prncpl Acctng Offcr
mixed-class rows
41,872
mixed-class rows
$76,536 18 May 2022
STATE STREET CORP
13F
Company
0.06%
19,554
$55,729 30 Sep 2024
13F
Ross Douglas T.
3/4/5
Former CSO
class O/S missing
234,114
$50,311 21 Dec 2022
NORTHERN TRUST CORP
13F
Company
0.05%
17,346
$49,436 30 Sep 2024
13F
Cavan M. Redmond
3/4/5
Director
class O/S missing
120,863
$25,973 24 Jun 2022
Mitchell S. Levine
3/4/5
Chief Financial Officer
mixed-class rows
174,580
mixed-class rows
$18,713 15 Mar 2022
Jennifer Levin Carter
3/4/5
Director
mixed-class rows
75,500
mixed-class rows
$6,554 15 Aug 2022
Melinda Griffith
3/4/5
Director
mixed-class rows
75,000
mixed-class rows
$6,447 15 Aug 2022
Tower Research Capital LLC (TRC)
13F
Company
0%
1,446
$4,121 30 Sep 2024
13F
OSAIC HOLDINGS, INC.
13F
Company
0%
1,080
$3,078 30 Sep 2024
13F
UBS Group AG
13F
Company
0%
835
$2,380 30 Sep 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
412
$1,173 30 Sep 2024
13F
Wilmington Savings Fund Society, FSB
13F
Company
0%
250
$713 30 Sep 2024
13F
JPMORGAN CHASE & CO
13F
Company
0%
154
$439 30 Sep 2024
13F
Piscataqua Savings Bank
13F
Company
0%
25
$71 30 Sep 2024
13F
Coppell Advisory Solutions LLC
13F
Company
0%
10
$29 30 Sep 2024
13F
ALBION FINANCIAL GROUP /UT
13F
Company
0%
7
$20 30 Sep 2024
13F
DANSKE BANK A/S
13F
Company
0%
1
$3 30 Sep 2024
13F
Anish M. John
3/4/5
Chief Financial Officer
class O/S missing
121,381
24 Feb 2023
Padmavathi Sundar
3/4/5
Chief Commercial Officer
class O/S missing
87,500
15 Mar 2022

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2024

As of 31 Dec 2024, Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by 1 institutional shareholder that filed Form 13F with the SEC. Together, they reported ownership of 47,078 shares. The largest 1 holders included Defender Capital, LLC.. This page lists 1 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2024 vs Q3 2024 Across Filers

Q3 2024 holders
1
Q4 2024 holders
1
Holder diff
0
Investor Q3 2024 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2024 Value $ Q4 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .